24 September 2024 - Approval based on results from positive, global, Phase 3 FRESCO-2 trial.

Takeda today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA 1 mg & 5 mg capsules (fruquintinib), a selective oral inhibitor of vascular endothelial growth factor receptor  -1, -2 and -3, for the treatment of advanced or recurrent colorectal cancer that is neither curable nor resectable and that has progressed after chemotherapy.

Read Takeda press release